Heart check after smallpox vaccine
Part of Infections clinical trials.
This study checks if the smallpox vaccine (JYNNEOS) causes heart inflammation (myocarditis) in military members getting it for the first time. It involves extra heart tests after your vaccine to make sure you're safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are active duty military, aged 18 to 45.
- You are getting the smallpox vaccine for the first time (never had it before).
- You have been cleared for the vaccine through standard medical screening.
- You are not pregnant and have no moderate or severe illness with fever.
- You have no planned deployment, PCS, or TDY for 65 days after your first visit.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a “registry,” meaning it collects medical information about people who develop possible heart inflammation after a COVID-19 vaccine. It may help doctors understand how often this happens and which findings are linked to it.
This trial tests a new monkeypox vaccine to see if it is safe and helps the body build protection. It may be an option for adults who were born before 1980 and received a smallpox vaccine, or who meet other health criteria.
This is a first-in-human safety study testing a new experimental immune therapy called JST-018. Researchers want to see how safe it is, how well your body tolerates it, and how your body processes it when given as an injection.
This early-phase trial tests a single or multiple doses of BSY001 to see if it is safe and how the body handles it. It is for healthy volunteers aged 18 to 50 who are not allergic to similar drugs and can avoid certain medicines and activities during the study.
This study tests a new injection (JYB1904) that may help control allergic reactions. It is for teenagers aged 12 to 17 who have had allergic conditions, to see if the drug is safe and how it works in this age group.
This trial looks at how well a medicine called VIGIV works for people who develop serious or unusual vaccinia (smallpox-type) infections or complications after smallpox vaccination. It is mainly for specific skin and body-area problems, including eczema-related complications.
Hear when a new Myopericarditis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.